CAR targeting CLEC2D and application thereof

By designing CAR-NK cells targeting CLEC2D and using them in combination with taurine, the problem of difficulty in identifying target antigens in solid tumors is solved, efficient killing of multiple solid tumors is achieved, and CAR-NK cell therapy is improved Treatment effect.

CN118930662AInactive Publication Date: 2024-11-12THE THIRD AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY +1
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411402301.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-09
Publication Date
2024-11-12
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing CAR-NK cell therapy has limited application in solid tumors, especially the difficulty in finding target antigens that are specifically expressed. At the same time, the effect of taurine on NK cell characteristics has not been reported, and there is a lack of CAR-targeting CLEC2D antigens. NK cell anti-tumor drug development.

Method used

Design a CAR targeting CLEC2D to construct CAR-NK cells and taurine by connecting human CD8a molecular signal peptide, CD161 extracellular region, CD8a flexible fragment, CD28 or 41BB transmembrane region with CD3z intracellular region. Used in combination to improve tumor cell killing ability.

Benefits of technology

The specific identification and killing of CLEC2D targets by CAR-NK cells has been achieved, and the therapeutic effect on a variety of solid tumors such as pancreatic cancer, cervical cancer, ovarian cancer, etc. has been enhanced. The tumor cells have been further improved through the synergistic effect of taurine. Can kill.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118930662A_ABST
    Figure CN118930662A_ABST
Patent Text Reader

Abstract

The invention relates to a CAR (Chimeric Antigen Receptor) targeting CLEC2D and application thereof, in particular to the CAR targeting CLEC2D, which is formed by sequentially connecting a human CD8a molecular signal peptide, a human CD161 extracellular region, a human CD8a molecular flexible fragment, a human CD28 molecular transmembrane region and intracellular region and a human CD3z molecular intracellular region in series, or the CAR is formed by sequentially connecting a human CD8a molecular signal peptide, a human CD161 extracellular region, a human CD8a molecular flexible fragment, a human 41BB molecular transmembrane region and intracellular region and a human CD3z molecular intracellular region in series. CAR-NK-cells obtained by expressing the CAR on NK cells can target CLEC2D antigens so as to treat tumors expressing CLEC2D, the CAR-NK-cells are combined with taurine to prepare anti-tumor drugs, and it is found that the killing capacity of the CAR-NK-cells on tumor cells can be improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biotechnology, and specifically relates to CAR targeting CLEC2D and applications thereof. Background Art

[0002] Chimeric antigen receptor (CAR) is a new type of receptor formed by fusing two or more different antigen-specific receptors or their fragments together through genetic engineering technology. Although CAR technology has made significant progress in T cell therapy, there are relatively few studies on CAR structural modification for NK cells. This is mainly because NK cells and T cells have significant differences in biological characteristics and functions. For example, the activation mechanism and signal transduction pathway of NK cells are different from those of T cells. Therefore, CAR structural modification for NK cells needs to overcome more technical difficulties. In addition, compared with T cells, using NK cells as host cells for CAR (chimeric antigen receptor) has significant benefits. NK cells naturally have strong anti-tumor activity and a wider range of tissue infiltration capabilities. They can directly kill a variety of tumor cells without prior sensitization and are not prone to induce graft-versus-host disease. The introduction of CAR technology into NK cells not only retains its powerful immune killing ability, but also enhances its recognition and attack on specific tumor antigens through the precise targeting of CAR, thereby improving the specificity and effectiveness of treatment. In addition, the immune response that NK cells may induce is milder than that of T cells, which helps to reduce the risk of serious side effects during treatment. Therefore, CAR-NK cell therapy shows great potential in anti-tumor treatment and provides patients with a safer and more effective treatment option.

[0003] In the existing technology, using CAR-NK cells to eliminate CD19+ tumor cells with CD19 as the target has shown good preventive and therapeutic effects in the treatment of acute lymphoblastic leukemia (ALL) of non-solid tumors. However, the application of CAR-NK technology in solid tumors is not satisfactory at present, and there are still many problems to be solved. One of the important technical problems is to find target antigens specifically expressed in solid tumors.

[0004] Studies on cell surface expressed molecules have shown that CLEC2D, as an immunoglobulin-like adhesion molecule, is involved in cell movement, natural killer and NK cells, and NK cell-mediated immune processes. CLEC2D plays an important role in immunity by interacting with CD161. Existing studies have shown that CLEC2D is rarely or weakly expressed in various normal human tissues, but is overexpressed in a variety of human malignant tumors, has a significant promoting effect on tumor proliferation and metastasis, and is associated with poor patient prognosis. For example, CLEC2D is expressed in large quantities in breast cancer. Based on this feature, using CLEC2D as a target and then developing a CAR-NK cell therapy method is expected to expand the application scope of CAR-NK technology in the treatment of solid tumors and further improve the treatment effect of tumors, which is of great technical significance.

[0005] Secondly, taurine is a sulfur-containing amino acid that exists in free form in animals but does not participate in protein synthesis. Studies have shown that taurine can promote the proliferation of T cells and B cells and enhance T cell immune function. There are currently no reports on taurine affecting the characteristics of NK cells, and there are no reports in the industry on the preparation of anti-tumor drugs using taurine combined with CAR-NK lymphocytes targeting CLEC2D antigens. Summary of the invention

[0006] In view of the shortcomings of the prior art, the present invention aims to provide a CAR targeting CLEC2D and its application, and specifically relates to a CAR (chimeric antigen receptor) targeting CLEC2D and its application. The CAR provided by the present invention is applied to NK cells to obtain CAR-NK cells, which can produce a synergistic effect when used in combination with taurine, further improving the killing ability of CAR-NK cells against tumor cells.

[0007] In order to achieve the above object, the present invention adopts the following technical solutions: The first object of the present invention is to provide a CAR targeting CLEC2D, wherein the CAR is composed of a human CD8a molecule signal peptide, a human CD161 extracellular region, a human CD8a molecule flexible fragment, a human CD28 molecule transmembrane region and intracellular region, and a human CD3z molecule intracellular region connected in series in sequence; or the CAR is composed of a human CD8a molecule signal peptide, a human CD161 extracellular region, a human CD8a molecule flexible fragment, a human 41BB molecule transmembrane region and intracellular region, and a human CD3z molecule intracellular region connected in series in sequence.

[0008] Preferably, the amino acid sequence encoding the CAR is shown in SEQ ID NO.1 or SEQ ID NO.2; the amino acid sequence of the human CD8a molecule signal peptide is shown in SEQ ID NO.3; the amino acid sequence of the human CD161 extracellular region is shown in SEQ ID NO.4; the amino acid sequence of the human CD8a molecule flexible fragment is shown in SEQ ID NO.5; the amino acid sequences of the transmembrane region and intracellular region of the human CD28 molecule are shown in SEQ ID NO.6; the amino acid sequences of the transmembrane region and intracellular region of the human 41BB molecule are shown in SEQ ID NO.7; the amino acid sequence of the intracellular region of the human CD3z molecule is shown in SEQ ID NO.8.

[0009] MALPVTALLLPLALLLHAARPQKSSIEKCSVDIQQSRNKTTERPGLLNCPIYWQQLREKCLLFSHTVNPWNNSLADCSTKESSLLLIRDKDELIHTQNLIRD KAILFWIGLNFSLSEKNWKWINGSFLNSNDLEIRGDAKENSCISISQTSVYSEYCSTEIRWICQKELTPVRNKVYPDSTTTPAPRPPTPAPTIASQPLSLRPE ACRPAAGGAVHTRGLDFACDFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYQ QGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPQRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO.1); MALPVTALLLPLALLLHAARPQKSSIEKCSVDIQQSRNKTTERPGLLNCPIYWQQLREKCLLFSHTVNPWNNSLADCSTKESSLLLIRDKDELIHTQNLIRDKAILFWIGLNFSLSEKNWKWINGSFLNSNDLEIRGDAKENSCISISQTSVYSEYCSTEIRWICQKELTPVRNKVYPDSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPQRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR(SEQ ID NO.2); MALPVTALLLPLALLLHAARP(SEQ ID NO.3); QKSSIEKCSVDIQQSRNKTTERPGLLNCPIYWQQLREKCLLFSHTVNPWNNSLADCSTKESSLLLIRDKDELIHTQNLIRDKAILFWIGLNFSLSEKNWKWINGSFLNSNDLEIRGDAKENSCISISQTSVYSEYCSTEIRWICQKELTPVRNKVYPDS(SEQ ID NO.4); TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACD(SEQ ID NO.5); FWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRS(SEQ ID NO.6); KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL(SEQ ID NO.7); RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPQRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO. 8).

[0010] The second object of the present invention is to provide a nucleic acid molecule comprising a nucleotide sequence encoding the above-mentioned CAR.

[0011] Preferably, the nucleotide sequence encoding the above-mentioned CAR is shown as SEQ ID NO.9 or SEQ ID NO.10.

[0012]

[0013] Another object of the present invention is to provide a vector, which comprises the above-mentioned nucleic acid molecule.

[0014] Preferably, the vector is a lentivirus containing the nucleic acid molecule.

[0015] Another object of the present invention is to provide a genetically engineered NK cell, wherein the NK cell expresses the CAR as described above that specifically recognizes CLEC2D.

[0016] Another object of the present invention is to provide the use of the above-mentioned CAR or nucleic acid molecule or vector or NK cell in the preparation of a pharmaceutical composition for treating tumors expressing CLEC2D.

[0017] Preferably, the tumor includes pancreatic cancer, cervical cancer, ovarian cancer, colorectal cancer, prostate cancer, lung cancer and liver cancer.

[0018] Another object of the present invention is to provide the use of the above-mentioned NK cells in combination with taurine in the preparation of a drug for treating tumors, wherein the CAS number of the taurine is 107-35-7 and the molecular formula is C2H7NO3S; and the tumor expresses CLEC2D.

[0019] Compared with the prior art, the present invention has the following beneficial effects: (1) The present invention uses CLEC2D as a target for the first time and provides a CAR targeting CLEC2D. The CAR provided by the present invention is specific for CLEC2D, and the CAR-NK cells obtained after the CAR-NK cells are expressed on NK cells have specific recognition for the CLEC2D target. The CAR-NK cells can target the CLEC2D antigen to treat tumors expressing CLEC2D, including pancreatic cancer, cervical cancer, ovarian cancer, colorectal cancer, prostate cancer, lung cancer and liver cancer.

[0020] (2) The present invention further combines taurine with the CAR-NK cells targeting the CLEC2D antigen of the present invention, and finds that they can exert a synergistic effect, further improving the killing ability of CAR-NK cells against tumor cells. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 Schematic diagram of the structure of CLEC2D-28z-CAR (top) and CLEC2D-BBz-CAR (bottom); Figure 2 Schematic diagram of the structure of pCDH-EF1-CAR-CLEC2D-28z (left) and pCDH-EF1-CAR-CLEC2D-BBz (right); Figure 3Flow cytometry was used to detect CAR expression on NK cells; Figure 4 is the proliferation of CAR-NK cells; Figure 5 CAR-NK cells can specifically kill CLEC2D-positive cells; Figure 6 CAR-NK cells targeting CLEC2D can effectively secrete effector factors after co-incubation with target cells; Figure 7 Diagram showing CAR-NK cells controlling tumor growth. DETAILED DESCRIPTION

[0022] The above contents of the present invention are further described in detail below by means of specific implementation methods in the form of examples, but this should not be understood as the scope of the above subject matter of the present invention being limited to the following examples.

[0023] Unless otherwise specified, the reagents used in the present invention are all conventional reagents, and the corresponding experimental operation methods and detection methods are all from conventional operation guides, such as the "Molecular Cloning Experiment Guide" and "Cell Experiment Guide" compiled by the Cold Spring Harbor Laboratory.

[0024] 1. Design principle / idea of ​​the present invention First, the present invention provides a CAR, which takes CLEC2D as the target and designs a new CAR structure based on the existing combination of human CD161 extracellular domain, CD8 signaling fragment, etc. In this structural design, the human CD161 extracellular domain is used as the CAR-NK cell recognition region to avoid immune rejection and help improve the treatment effect; and the addition of intracellular stimulation signals CD28 or 41BB is to improve NK cell function.

[0025] Secondly, based on this CAR structure design, the inventors further prepared a recombinant lentiviral expression plasmid targeting CLEC2D. Further NK cell transfection and related preliminary experimental results showed that the relevant CAR structure design can effectively stimulate tumor cells to produce a large amount of effector factor IFN-γ, indicating that the CAR structure has good application prospects for the prevention and treatment of related tumors, especially solid tumors.

[0026] In addition, because taurine has been reported to play an important role in immune regulation, the inventors were inspired to combine taurine with the construction of CAR-NK cells, and also proved that CAR-NK cells have good anti-tumor effects through co-incubation and mouse tumor-bearing experiments; further, through combined drug experiments, it was verified that CLEC2D-CAR-NK cells can be used in combination with taurine, which can promote the proliferation of CAR-NK cells and thus have a better anti-tumor effect, and it can be prepared into a combined preparation that has an in vitro killing effect on tumor cells.

[0027] Example 1 Design of CAR molecules and preparation of CAR-NK cells (1) Design of CAR molecules Considering the differences in molecular expression between tumor cells and normal cells, based on the accumulation of previous work, in the present invention, the inventors selected CLEC2D as the target. At the same time, based on the inventors' previous experience in CAR structure design, the inventors designed a new CAR structure - a CAR structure targeting CLEC2D. The specific structure is as follows: Figure 1 As shown, they are named as: CLEC2D-28z-CAR or CLEC2D-BBz-CAR, and the specific descriptions are as follows: Among them, the CLEC2D-28z-CAR structure includes a human CD8a molecule signal peptide (Leadingsignal, CD8a), a human CD161 extracellular region (human CLEC2D extracellular region), a human CD8a molecule flexible fragment (CD8 Hinge), a human CD28 molecule transmembrane region and intracellular region (CD28) and a human CD3z molecule intracellular region (CD3z) connected in sequence; the total length of the protein is 406 amino acids, and the specific amino acid sequence is shown in SEQ ID No.1.

[0028] The CLEC2D-BBz-CAR structure includes a human CD8a molecule signal peptide (Leading signal), a human CD161 extracellular region (human CLEC2D extracellular region), a human CD8a molecule flexible fragment (CD8 Hinge), a human 41BB molecule transmembrane region and intracellular region (41BB) and a human CD3z molecule intracellular region (CD3z) connected in sequence; the total length of the protein is 380 amino acids, and the specific amino acid sequence is shown in SEQ ID No.2.

[0029] The amino acid sequence of the human CD8a molecule signal peptide (CD8a) comprises 21 amino acids, as specifically shown in SEQ ID NO.3; The amino acid sequence of the human CD161 extracellular region (human CLEC2D extracellular region) comprises 159 amino acids, as specifically shown in SEQ ID NO.4; The amino acid sequence of the human CD8a molecule flexible fragment (CD8 Hinge) includes 45 amino acids, as specifically shown in SEQ ID NO.5; The amino acid sequence of the transmembrane region and intracellular region (CD28) of the human CD28 molecule comprises 68 amino acids, as specifically shown in SEQ ID NO.6; The amino acid sequence of the transmembrane region and intracellular region (41BB) of the human 41BB molecule includes 42 amino acids, as specifically shown in SEQ ID NO.7; The amino acid sequence of the intracellular region of the human CD3z molecule (CD3z) includes 113 amino acids, as specifically shown in SEQ ID NO.8.

[0030] It should be explained that in the design of CAR structure, the selection of human CD161 extracellular domain as the CAR-NK cell recognition region can effectively avoid immune rejection, thus helping to improve the therapeutic effect. The addition of intracellular stimulation signals (CD28 or 41BB) can improve NK cell function.

[0031] According to the amino acid sequences SEQ ID NO.1 and SEQ ID NO.2 of CLEC2D-BBz-CAR and CLEC2D-BBz-CAR, Shanghai Shenggong Company was commissioned to synthesize and prepare the corresponding DNA coding sequences, wherein the nucleotide sequence encoding CLEC2D-BBz-CAR is shown in SEQ ID NO.9, and the nucleotide sequence encoding CLEC2D-BBz-CAR is shown in SEQ ID NO.10.

[0032] (2) Construction of recombinant lentiviral expression plasmid The pCDH-EF1-conGFP plasmid was used as an expression vector, which was digested with EcoR I, and then the gene sequence in step (1) was integrated and recombined into the pCDH-EF1-conGFP plasmid; the manufacturer of the In-Fusion HD Cloning Kits is Clontech, and the product number is 639649. The ligation product was transformed into STABL3 competent cells, and the plasmid was further extracted after screening and expansion culture to construct a lentiviral vector pCDH-EF1-CAR-CLEC2D-28z or pCDH-EF1-CAR-CLEC2D-BBz expressing the CAR structure.

[0033] The schematic diagram of the structure of the lentiviral expression plasmid pCDH-EF1-CAR-CLEC2D-28z or pCDH-EF1-CAR-CLEC2D-BBz is shown in Figure 2 shown.

[0034] (3) Lentiviral packaging The specific packaging operations can be referred to as follows: 293T cells (cell bank of the Chinese Academy of Sciences Typical Culture Collection Committee, model SCSP-502) were used as packaging cells. After 293T cells were plated for 24 hours (cell fusion rate reached about 80%), two 1.5mL Ep tubes were prepared and 0.5mL Opti-MEM medium (purchased from Thermo Fisher Scientific, catalog number 31985070) was added. In one tube, pCDH-EF1-CAR-CLEC2D-28z or pCDH-EF1-CAR-CLEC2D-BBz expression plasmids and packaging plasmids (pSPAX2 and pMD2.G) were mixed (the molar ratio of the three plasmids was 1:1:1, and the total mass was 4ug). After mixing, the mixture was incubated at room temperature (22-25°C) for 5 minutes. Lipofectamine 3000 was added to the other tube. Then, the medium containing plasmids and Lipo was mixed and incubated at room temperature for 20 minutes. Carefully add the plasmid-Lipo mixture to 293FT cells. After 16-18 hours of transfection, carefully remove the supernatant, then slowly add 3 mL of DMEM containing 10% serum and culture statically.

[0035] 48 hours after transfection, the supernatant was collected for subsequent NK cell infection.

[0036] (4) NK cell purification and infection In order to construct CAR-NK cells, NK cells were purified and subjected to virus infection experiments.

[0037] Peripheral blood was collected from healthy donors and centrifuged by density gradient centrifugation. The supernatant was discarded and pre-cooled 1× Buffer was added to adjust the cell density to 1×10 8 / mL. Transfer 2mL of cell suspension to a sterile flow tube, add 200L Human NK Cell Biotinylated Antibody Cocktail (purchased from BD, catalog number 557987), mix gently and incubate at 4°C for 15min. Add 250L Streptavidin Ferrofluid (streptavidin iron magnet), mix carefully, and incubate at 4°C for 15min. Add 0.55mL pre-cooled 1×Buffer to 3mL, mix gently and place the flow tube containing the cell suspension on the magnetic sorting rack, let it stand at room temperature for 6min, and carefully transfer the suspension to a new sterile tube. This part of the cells is the NK cells. Use cell culture medium (Dakewe, DKW37-NKP001) supplemented with 10% human serum (Sigma, H4522) for culture; After 2 weeks, add the virus supernatant collected in (3) (2 mL per well of a 6-well plate) and polybrene (10 L per well of a 6-well plate) and incubate overnight; The next day, NK cells were washed by centrifugation three times, and then RPMI1640 medium (ThermoFisher Scientific, 12633012) containing 1000 U IL-2 and 5% human serum (Sigma, H4522) was added to expand NK cells.

[0038] (5) Transfection efficiency detection After 7 days of NK cell infection in step (4), the expression of CAR on the surface of NK cells was analyzed using a C6 flow cytometer (Becton Dickinson), and the data were analyzed using FlowJo software (FlowJo, LLC, Ashland, Covington, KY, USA). The expression of fluorescent protein GFP represents the expression of CAR. After the test is qualified (GFP positive rate ≥ 50%), the transfected CAR-NK cells were further expanded in vitro in RPMI1640 medium containing 1000U IL-2 and 5% fetal bovine serum.

[0039] The experimental results are as follows Figure 3 As shown in the figure, the flow cytometry test results showed that the CAR expression positive rate could reach 60~70%. This result indicated that the CAR expression plasmid construction and virus packaging were successful, which could lay the foundation for subsequent applications.

[0040] In order to further study the performance of CAR-NK cells, the following experiments mainly used CLEC2D-BBz-CAR-NK cells.

[0041] Example 2 CAR-NK cell proliferation detection In order to verify the effect of taurine on NK cell proliferation, the constructed CLEC2D-BBz-CAR-NK cells were cultured with taurine in vitro.

[0042] Detection of the optimal concentration of taurine for proliferation activity: In order to further clarify the specific concentration of taurine on the proliferation of CAR-NK cells, the transfected CAR-NK cells were cultured with medium containing 0, 30, 60, and 120 μM taurine, and the taurine concentration suitable for CAR-NK cell proliferation was analyzed by cell counting two days later. The specific steps include the following: 6-well culture plates were used to culture NK cells, and the number of cells was 2×10 5 Different concentrations of taurine were added to the culture medium. After culturing in the incubator for 2 days, the cell concentrations of different treatment groups were counted using a counting plate to compare the differences in the number of NK cells treated with different concentrations of taurine.

[0043] like Figure 4As shown in (A), CAR-NK cells showed the best proliferation activity when the taurine concentration was 60 μM; further CAR-NK cell proliferation was shown in Figure 4 (B) (1×10 6 Based on the transfected NK cells, the counts were performed at 7, 10 and 14 days of amplification, respectively). It can be seen that the transfected CAR-NK cells can proliferate efficiently and the CAR-NK cells cultured with taurine have more obvious proliferation. This shows that the CAR structure provided by the present invention has no obvious effect on the activity of NK cells, while taurine has a promoting effect on the proliferation of NK cells.

[0044] Example 3 In vitro killing effect of CAR-NK cells In order to verify the ability of CLEC2D-BBz-CAR-NK cells to target and kill CLEC2D+ tumor cells, an in vitro co-culture experiment was performed on the constructed CLEC2D-BBz-CAR-NK cells.

[0045] Select the CLEC2D-BBz-CAR-NK cells transfected 14 days after Example 1, count the NK cells and target cells, and use the cell dye (eFluor670) to mark the target cells; then, according to the effector-target ratio (Effector cell: target cell, E:T) of 1:1, 5:1, and 20:1, the transfected NK cells (effector cells) were incubated with CLEC2D high-expressing target cells (breast cancer cell line AU565, purchased from the cell bank of the Institute of Life Sciences) and CLEC2D negative control cells (normal breast cell line MCF10A, purchased from the cell bank of the Institute of Life Sciences) for 8 hours. According to different treatment methods, it was divided into 4 experimental groups, namely the control group (the control group was infused with Mock-NK cells), the taurine group, the CLEC2D-CAR-NK cell group, and the taurine combined with the CLEC2D-CAR-NK cell group (the taurine concentration was 60 μM / mL).

[0046] After the co-incubation, the cells were collected by centrifugation, resuspended in Annexin V-binding buffer (BioLegend, SanDiego, CA, USA), and then incubated at 4°C in a dark environment for 15 minutes. Propidium (Sigma) was added before loading. The cells were detected and analyzed using a C6 flow cytometer (Becton Dickinson), and the data were analyzed using FlowJo software (FlowJo, LLC, Ashland, Covington, KY, USA).

[0047] The experimental results are as follows Figure 5 As shown. The analysis shows that taurine itself has no obvious inhibitory effect on tumor cells, while CAR-NK cells have a strong killing ability on tumor cells expressing CLEC2D, and have little effect on CLEC2D negative cells. After further treatment with taurine, the killing ability of CAR-NK cells on tumor cells expressing CLEC2D is enhanced, indicating that the CAR-NK cells have a strong specific killing ability, and the combination of taurine can further improve the killing ability of CAR-NK cells on tumor cells.

[0048] Furthermore, the culture supernatant was collected after 8 hours of co-incubation to detect the secretion of effector factors in the culture supernatant. The results of the ELISA experiment showed (taking the effector-target ratio of 20:1 as an example) that CAR-NK cells produced a large amount of effector factor IFN-γ after co-incubation with tumor cells expressing CLEC2D, and the ability of CAR-NK cells combined with taurine to secrete effector factors was stronger, while co-incubation with CLEC2D-negative cells did not have this effect; Figure 6 As shown in the figure, control NK cells co-incubated with tumor cells could not produce a large number of effector factors, and the taurine-treated group did not secrete effector factors. This result further shows that CAR-NK cells combined with taurine have stronger specific killing ability.

[0049] Example 4 Animal Experiment In order to verify the anti-tumor activity of CLEC2D-BBz-CAR-NK cells, mouse tumor-bearing experiments were performed on the constructed CLEC2D-BBz-CAR-NK cells.

[0050] NOD-SCID immunodeficient mice were purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd. and inoculated subcutaneously with 5×10 5 AU565 cells were injected into the tail vein 7 days later with 5×10 6 The CAR-NK cells prepared above (solvents were PBS or PBS dissolved with 60 μM / mL taurine), control NK cells (Mock-NK) or taurine alone were treated.

[0051] Then, the fluorescence was detected on days 0, 7, 14, and 21 after injection using the small animal in vivo imaging device IVIS Lumina, Series Ⅲ spectrometer (Caliper Life Science), and finally analyzed using live image4.3.1 software (PerkinElmer, Waltham, MA, USA).

[0052] The experimental results are as follows Figure 7As shown. It can be seen that 7 days after injection of the CAR-NK cell group and the CAR-NK cell group combined with taurine (as shown Figure 7 (A)), the tumor volume was significantly reduced, and as the treatment time prolonged, the tumor volume of the CAR-NK cell treatment group combined with taurine became smaller and smaller compared with the other three groups (as shown in Figure 7 (B) ), the control NK cells or taurine treatment alone had no effect on tumor growth, suggesting that CAR-NK cells combined with taurine have good tumor killing ability.

[0053] The above embodiments are merely illustrative of the principles and effects of the present invention, and are not intended to limit the present invention. Anyone familiar with the art may modify or alter the above embodiments without departing from the spirit and scope of the present invention. Therefore, all equivalent modifications or alterations made by a person of ordinary skill in the art without departing from the spirit and technical concept disclosed by the present invention shall still be covered by the claims of the present invention.

Claims

1. A CAR targeting CLEC2D, characterized in that: The CAR is composed of a human CD8a molecule signal peptide, a human CD161 extracellular region, a human CD8a molecule flexible fragment, a human CD28 molecule transmembrane region and intracellular region, and a human CD3z molecule intracellular region connected in series in sequence; or the CAR is composed of a human CD8a molecule signal peptide, a human CD161 extracellular region, a human CD8a molecule flexible fragment, a human 41BB molecule transmembrane region and intracellular region, and a human CD3z molecule intracellular region connected in series in sequence.

2. The CAR targeting CLEC2D according to claim 1, characterized in that The amino acid sequence encoding the CAR is shown in SEQ ID NO.1 or SEQ ID NO.2; the amino acid sequence of the human CD8a molecule signal peptide is shown in SEQ ID NO.3; the amino acid sequence of the human CD161 extracellular region is shown in SEQ ID NO.4; the amino acid sequence of the human CD8a molecule flexible fragment is shown in SEQ ID NO.5; the amino acid sequences of the transmembrane region and intracellular region of the human CD28 molecule are shown in SEQ ID NO.6; the amino acid sequences of the transmembrane region and intracellular region of the human 41BB molecule are shown in SEQ ID NO.7; the amino acid sequence of the intracellular region of the human CD3z molecule is shown in SEQ ID NO.

8.

3. A nucleic acid molecule, characterized in that The nucleic acid molecule comprises a nucleotide sequence encoding the CAR of claim 1.

4. The nucleic acid molecule according to claim 3, characterized in that The nucleotide sequence encoding the CAR according to claim 1 is shown as SEQ ID NO.9 or SEQ ID NO.

10.

5. A carrier, characterized in that The vector comprises the nucleic acid molecule of claim 3 or 4.

6. The carrier according to claim 5, characterized in that The vector is a lentivirus containing the nucleic acid molecule.

7. A genetically engineered NK cell, characterized in that: The NK cells express the CAR according to claim 1 that specifically recognizes CLEC2D.

8. Use of the CAR according to any one of claims 1 to 2, or the nucleic acid molecule according to any one of claims 3 to 4, or the vector according to any one of claims 5 to 6, or the NK cell according to claim 7 in the preparation of a pharmaceutical composition for treating a tumor expressing CLEC2D.

9. The use according to claim 8, characterized in that: Such tumors include pancreatic cancer, cervical cancer, ovarian cancer, colorectal cancer, prostate cancer, lung cancer and liver cancer.

10. The use of NK cells and taurine in combination in the preparation of a drug for treating tumors according to claim 7, characterized in that: The CAS number of the taurine is 107-35-7, and the molecular formula is C2H7NO3S; the tumor expresses CLEC2D.

Citation Information

Patent Citations

  • Chimeric antigen receptor based on human CD20 antibody, lentiviral expression vector and applications of chimeric antigen receptor

    CN109608548A

  • CD155-targeting CAR structure design and application thereof

    CN114957483A

  • CAR molecule, CAR cell, CAR pharmaceutical composition and application thereof

    CN118221828A

  • Methods and compositions for treating cancer by targeting the CLEC2d-KLRB1 pathway

    WO2019094983A1